TUBERCULOSIS
THE UNMET NEED OF TB
Tuberculosis is one of the deadliest infectious diseases and amongst the top 10 causes of death on earth.
In 2020 an estimated 10 million people became ill with tuberculosis, (TB) and 1.5 million people died (400,000 of them children).
TB is preventable and curable, however, 98% of reported cases are from lower income & middle income countries (LIMICs) who’s funding falls far short of what is needed.
Additionally, Multidrug-resistant TB (MDR-TB) remains a public health crisis and a health security threat. Only about one in three people with drug resistant TB accessed treatment in 2020.
Dr. Özlem Türeci, co-Founder of BioNTech and Akagera Med co-Founder, Dr. Daryl Drummond, meet in Kigali. Both focussed their entire careers on treatments for Cancer and Infectious Diseases.
“It’s a shame, because the history of tuberculosis control is really one of forgetting. This is a transnational disease. ”
April 24, 2024 Rwandan-owned Akagera Medicines’ first GMP batch, which will be used to support our upcoming Phase 1 TB clinical trial in Africa.
“Innovation often comes from taking insights from one field of science, and applying them to the challenges of another. We are translating next generation nanotechnologies in oncology to the fight against neglected infectious diseases.”
Our Science
(AKAGERA MEDICINES HAS ACHIEVED preclinical proof of concept)
technology
Liposomal Nanotherapeutics represent a well-validated platform of drug delivery systems which are utilized to alter the biodistribution of the encapsulated drug and the exposure profile for the drug, impacting both the efficacy and the toxicity (the therapeutic index) of the active drug.
mechanism of action
Additional Resources & News